AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns
Executive Summary
AstraZeneca will delay an NDA filing for its dual PPAR Galida (tesaglitazar) until 2007 in order to gather two years of long-term follow-up data
You may also be interested in...
Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says
Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says
Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership
Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)